Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH EBITDA Margin

EBITDA as a percentage of revenue.

Accendra Health, Inc.NYSE: ACH

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 8.9%

EBITDA Margin was 8.9% in Q1 FY2026, up 6.6 pp from a year earlier. On a trailing-twelve-month basis it was 12.7%, up 12.2 pp year over year. Over 3 fiscal years it widened by 9.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 12.9% for the fiscal year ending Dec 2026, down from 13.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
8.9%-3.4 pp QoQ
Last fiscal yearDec 2025
13.2%+12.7 pp YoY
LTMMar 2026
12.7%+12.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.6 pp-1.0 pp-7.6 pp
1 year+12.7 pp-0.3 pp-13.0 pp
3 years+9.5 pp-1.7 pp-11.2 pp
5 years-0.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
13.2%
Year-over-year change
+12.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ACH compares with its peers on the latest reported figures

  • ACH's LTM Mar 2026 EBITDA Margin of 12.7% is the highest of the 9 companies compared; the peer median is -71.8%.
  • Its year-over-year change of +12.2 pp is the 6th highest of 9, against a peer median of +16.3 pp.
  • Over three fiscal years its change of +9.5 pp compares with a peer median of +80.2 pp.
ACH Competitors Peer median
EBITDA Margin for ACH and competitors
Company Period LTM level YoY 3-year change
ACHAccendra Health, Inc.LTM Mar 202612.7% +12.2 pp+9.5 pp
HITIHigh Tide Inc.LTM Apr 2026-0.9% -5.9 pp+7.1 pp
SGHTSight Sciences, Inc.LTM Mar 2026-39.8% +16.3 pp+70.4 pp
OMOutset Medical, Inc.LTM Mar 2026-53.0% +16.3 pp+80.2 pp
CGCCanopy Growth CorporationLTM Mar 2026-65.7% +112.4 pp+874.7 pp
CVRXCVRx, Inc.LTM Mar 2026-77.8% +9.1 pp+98.8 pp
EDITEditas Medicine, Inc.LTM Mar 2026-258.7% +387.8 pp+719.4 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
BIOABioAge Labs, Inc.LTM Mar 2026-864.8% +3922.9 pp—
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
Peer median (excluding ACH) -71.8%+16.3 pp+80.2 pp

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.